Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Childhood Cancer, Cardiac Toxicity, Pediatric Cancer
Interventions
Computerized Intervention Authoring Software (CIAS)
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
St Louis, Missouri
Not listed Not applicable Interventional Accepts healthy volunteers

Ambulatory Medication Reconciliation Following Hospital Discharge

NCT00740675
Conditions
Medication Administered in Error, Adverse Drug Events
Interventions
Outpatient Medication Reconciliation
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
55 Years and older
Enrollment
912 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Dyslipidemia
Interventions
Educational content on statin side effects
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
Weight Gain, Autism Spectrum Disorder, Medication Side Effect
Interventions
Comparison of Risperidone and Aripiprazole
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Up to 17 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Completed Not applicable Interventional Results available

Sonoelastography: Ultrasound Method to Measure Liver Fibrosis

NCT01747772
Conditions
Chronic Liver Disease, Non-Alcoholic Fatty Liver Disease, Hepatitis C Virus (HCV) Coinfection, Hepatitis B Virus (HBV), Drug-Induced Liver Injury
Interventions
Shear Wave Sonoelastography
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Active, not recruiting No phase listed Observational

Biomarkers of Immune-Related Toxicity

NCT03409016
Conditions
Cancer, Metastatic Cancer
Interventions
Blood Testing
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Drug/Agent Toxicity by Tissue/Organ, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
amifostine trihydrate
Drug
Lead sponsor
Rush North Shore Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2004
U.S. locations
1
States / cities
Skokie, Illinois
Conditions
Chemo Fog
Interventions
Ashwagandha, Placebo
Drug
Lead sponsor
Sutter Health
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Sacramento, California
Completed Phase 4 Interventional Accepts healthy volunteers Results available

FLUAD® vs. Fluzone® High-Dose Study

NCT03183908
Conditions
Pain, Quality of Life, Injection Site Reaction, Side Effect of Drug, Adverse Drug Event
Interventions
FLUAD®, Fluzone® High-Dose
Biological
Lead sponsor
Duke University
Other
Eligibility
65 Years and older
Enrollment
757 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
4
States / cities
Atlanta, Georgia • Boston, Massachusetts • Durham, North Carolina + 1 more
Conditions
Drug/Agent Toxicity by Tissue/Organ, Lung Cancer
Interventions
amifostine trihydrate, cisplatin, docetaxel
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Upper Limb Essential Tremor
Interventions
AGN-151607-DP, Placebo for AGN-151607-DP
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 85 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Fresno, California • Boca Raton, Florida • Orlando, Florida
Conditions
Cancer Survivor, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Cognitive Side Effects of Cancer Therapy
Interventions
Educational Intervention, Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Not listed
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Duarte, California
Conditions
Acute Kidney Injury
Interventions
Level A, Level B, Passive Alert
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
8
States / cities
Altoona, Pennsylvania • Farrell, Pennsylvania • McKeesport, Pennsylvania + 3 more
Conditions
Parkinson Disease
Interventions
Continuous Release Dopamine Agonists
Drug
Lead sponsor
University of Toledo
Other
Eligibility
55 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Toledo, Ohio
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Long-Acting Reversible Contraception

NCT01299116
Conditions
Contraception
Interventions
DMPA, oral contraceptives, Implanon®, ParaGard®, Mirena®
Drug
Lead sponsor
FHI 360
Other
Eligibility
18 Years to 29 Years · Female only
Enrollment
916 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Completed Not applicable Interventional Accepts healthy volunteers

Preventing Adverse Drug Events With PatientSite

NCT00140504
Conditions
Adverse Drug Event
Interventions
Medcheck message
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Cystic Fibrosis
Interventions
RETRIAL-Mental Health, RETRIAL-Liver, RETRIAL-Neuro
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Aurora, Colorado • Denver, Colorado + 14 more
Conditions
Coronary Microvascular Dysfunction, Cardiotoxicity, Breast Cancer, Lung Cancer (NSCLC)
Interventions
Not listed
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Phase 1Phase 2 Interventional Results available

Pilot Study of an NTproBNP Guided Strategy of Cardioprotection

NCT04737265
Conditions
Cardiotoxicity, Toxicity Due to Chemotherapy, Breast Cancer, Lymphoma, Cardiomyopathies, Heart Failure
Interventions
Biomarker Guided Intervention
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Duarte, California • Philadelphia, Pennsylvania • West Chester, Pennsylvania
Conditions
Dyskinesia, Drug-Induced
Interventions
Quetiapine, Risperidone, Olanzapine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
40 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
San Diego, California
Conditions
Parkinson Disease, Dyskinesia, Drug-Induced, Levodopa
Interventions
AFQ056
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Sunnyvale, California • Englewood, Colorado • Indianapolis, Indiana
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

COVID-19 Reactogenicity

NCT07051031
Conditions
COVID-19
Interventions
Nuvaxovid (NVX-CoV2705), mNEXSPIKE mRNA-1283
Drug
Lead sponsor
Marcel Curlin
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Intensive Care Unit Syndrome, Mechanical Ventilation Complication, Sedatives and Hypnotics Causing Adverse Effects in Therapeutic Use, Delirium
Interventions
Not listed
Lead sponsor
Interfaith Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Conditions
Migraine
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,884 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2036
U.S. locations
1
States / cities
Durham, North Carolina